产品
编 号：F748416
分子量：6364.1
分子量：6364.1
产品类型
规格
价格
是否有货
结构图
CAS No: 202668-42-6
产品详情
生物活性：
ODN 1826 (CpG 1826), a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN 1826 promotes Apoptosis. ODN 1826 is an excellent immune stimulator with antitumor activity. ODN 1826 has protective effects on the heart. ODN 1826 sequence: 5’-tccatgacgttcctgacgtt-3’.
体内研究：
ODN 1826 (18 nM, 皮下注射, 一周3次共7周) 在慢性血管损伤小鼠模型中增加主动脉粥样硬化斑块大小。ODN 1826 (0.05 mg, 腹腔注射, 1，3，5，8，11，13天) 在 Lewis 肺癌小鼠肿瘤模型中具有较强的抗肿瘤生长作用 。Animal Model:Chronic vascular injury mouse models
Dosage:18 nM CPG ODN
Administration:s.c,three times a week for 7 weeks
Result:Increased in aortic atherosclerotic plaque size compared to vehicle.
Animal Model:Lewis Lung Cancer Murine Tumor Model
Dosage:0.05 mg (1, 3, 5, 8, 11, 13 days)
Administration:Intraperitoneal injection (i.p.)
Result:Delayed tumor growth,decreased tumor weight and increased the apoptosis of tumor cells.
体外研究：
ODN 1826 (1 μg/mL, 24 h) 在 RAW 264.7 细胞中可以刺激 NO 和 iNOS 的产生。
ODN 1826 (CpG 1826), a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN 1826 promotes Apoptosis. ODN 1826 is an excellent immune stimulator with antitumor activity. ODN 1826 has protective effects on the heart. ODN 1826 sequence: 5’-tccatgacgttcctgacgtt-3’.
体内研究：
ODN 1826 (18 nM, 皮下注射, 一周3次共7周) 在慢性血管损伤小鼠模型中增加主动脉粥样硬化斑块大小。ODN 1826 (0.05 mg, 腹腔注射, 1，3，5，8，11，13天) 在 Lewis 肺癌小鼠肿瘤模型中具有较强的抗肿瘤生长作用 。Animal Model:Chronic vascular injury mouse models
Dosage:18 nM CPG ODN
Administration:s.c,three times a week for 7 weeks
Result:Increased in aortic atherosclerotic plaque size compared to vehicle.
Animal Model:Lewis Lung Cancer Murine Tumor Model
Dosage:0.05 mg (1, 3, 5, 8, 11, 13 days)
Administration:Intraperitoneal injection (i.p.)
Result:Delayed tumor growth,decreased tumor weight and increased the apoptosis of tumor cells.
体外研究：
ODN 1826 (1 μg/mL, 24 h) 在 RAW 264.7 细胞中可以刺激 NO 和 iNOS 的产生。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备